| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Dec 12 | Option Exercise | 54.86 | 42,370 | 2,324,418 | 56,207 | Dec 14 05:06 PM | | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Dec 12 | Sale | 163.44 | 42,370 | 6,925,018 | 13,837 | Dec 14 05:06 PM | | SEVERINO MICHAEL | Vice Chairman | May 23 | Option Exercise | 108.99 | 79,801 | 8,697,627 | 231,904 | May 25 04:58 PM | | SEVERINO MICHAEL | Vice Chairman | May 23 | Sale | 150.90 | 79,801 | 12,041,780 | 152,103 | May 25 04:58 PM | | SEVERINO MICHAEL | Vice Chairman | May 17 | Option Exercise | 88.38 | 100,000 | 8,837,929 | 252,103 | May 18 05:12 PM | | SEVERINO MICHAEL | Vice Chairman | May 17 | Sale | 154.04 | 100,000 | 15,404,400 | 152,103 | May 18 05:12 PM | | SEVERINO MICHAEL | Vice Chairman | May 16 | Option Exercise | 66.50 | 100,000 | 6,650,277 | 252,103 | May 18 05:12 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | May 16 | Option Exercise | 54.86 | 83,960 | 4,606,046 | 100,583 | May 18 05:12 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | May 16 | Sale | 155.00 | 83,960 | 13,013,800 | 16,623 | May 18 05:12 PM | | SEVERINO MICHAEL | Vice Chairman | May 16 | Sale | 154.45 | 100,000 | 15,445,089 | 152,103 | May 18 05:12 PM | | SEVERINO MICHAEL | Vice Chairman | May 10 | Option Exercise | 59.60 | 100,000 | 5,960,468 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 10 | Sale | 152.28 | 100,000 | 15,227,966 | 152,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 09 | Option Exercise | 56.21 | 100,000 | 5,621,478 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 09 | Sale | 150.28 | 100,000 | 15,027,710 | 152,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 06 | Option Exercise | 54.55 | 100,000 | 5,454,790 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 06 | Sale | 150.81 | 100,000 | 15,080,612 | 152,103 | May 10 05:05 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 24 | Option Exercise | 58.88 | 27,690 | 1,630,387 | 88,631 | Mar 25 05:09 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 24 | Sale | 159.20 | 27,690 | 4,408,375 | 60,941 | Mar 25 05:09 PM | | Durkin Brian L | VP, Controller | Mar 09 | Option Exercise | 79.02 | 11,682 | 923,112 | 37,722 | Mar 11 05:05 PM | | Durkin Brian L | VP, Controller | Mar 09 | Sale | 150.01 | 18,628 | 2,794,301 | 19,094 | Mar 11 05:05 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Mar 01 | Sale | 147.29 | 25,000 | 3,682,189 | 16,623 | Mar 02 05:03 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 01 | Sale | 148.25 | 21,488 | 3,185,599 | 60,941 | Mar 01 06:08 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Mar 01 | Sale | 148.26 | 15,000 | 2,223,836 | 41,623 | Mar 01 06:14 PM | | Michael Robert A. | Vice Chairman | Mar 01 | Sale | 148.25 | 43,105 | 6,390,247 | 37,877 | Mar 01 06:07 PM | | Strom Carrie C | SVP & Pres Global Allerg Aesth | Feb 07 | Sale | 141.17 | 2,396 | 338,243 | 42,499 | Feb 08 05:13 PM |
|
